Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
A Phase 4, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Single-dose, Five-way Crossover Study Evaluating the Abuse Potential of Three Doses of NEURONTIN® Taken Orally in Healthy, Non-drug Dependent Participants With Sedative Drug Abuse Experience
Sponsor: Viatris Specialty LLC
Listed as NCT04570436, this PHASE4 trial focuses on Abuse Potential and remains completed. Sponsored by Viatris Specialty LLC, it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE4
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jan 2024 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Apr 2022 — Jan 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Apr 2022 [monthly]
Not Yet Recruiting PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Viatris Specialty LLC
For direct contact, visit the study record on ClinicalTrials.gov .